The European Medicines Agency (EMEA) has recommended the withdrawal of the marketing authorisations for all lumiracoxib-containing medicines, because of the risk of serious side effects affecting the liver. Lumiracoxib is a non-steroidal anti-inflammatory drug (NSAID) that belongs to the group ‘COX-2 inhibitors’. It is used for symptomatic relief in the treatment of osteoarthritis of the hip and knee.
Source: http://www.emea.europa.eu/pdfs/human/press/pr/PR_Lumiracoxib_57930107en.pdf
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment